Foster Victor Wealth Advisors LLC Purchases 60,667 Shares of Pfizer Inc. $PFE

Foster Victor Wealth Advisors LLC raised its position in shares of Pfizer Inc. (NYSE:PFE) by 9.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 705,258 shares of the biopharmaceutical company’s stock after purchasing an additional 60,667 shares during the quarter. Pfizer accounts for approximately 1.2% of Foster Victor Wealth Advisors LLC’s holdings, making the stock its 24th biggest position. Foster Victor Wealth Advisors LLC’s holdings in Pfizer were worth $19,303,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in PFE. Fiduciary Alliance LLC boosted its stake in shares of Pfizer by 46.4% during the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock worth $3,701,000 after acquiring an additional 46,043 shares during the last quarter. Westbourne Investments Inc. purchased a new stake in shares of Pfizer in the 1st quarter worth $2,411,000. Bourne Lent Asset Management Inc. raised its holdings in Pfizer by 90.8% in the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock worth $927,000 after purchasing an additional 18,200 shares during the period. Ossiam lifted its position in Pfizer by 71.2% during the second quarter. Ossiam now owns 5,650,573 shares of the biopharmaceutical company’s stock valued at $136,970,000 after purchasing an additional 2,349,058 shares in the last quarter. Finally, Strs Ohio bought a new stake in Pfizer during the first quarter valued at about $49,968,000. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on PFE shares. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the stock an “underperform” rating in a research report on Wednesday. Sanford C. Bernstein reissued a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a research note on Friday, October 31st. Finally, Bank of America lowered their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $28.06.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Scotiabank reaffirmed a Buy on PFE, signaling continued analyst conviction from some firms despite the weak outlook. Scotiabank Reaffirms Buy
• Positive Sentiment: Pfizer moved to strengthen its obesity pipeline by licensing a weight-loss drug from Fosun, a strategic push into a high-growth market that could drive medium-term revenue upside if commercialization succeeds. Pfizer licenses weight-loss drug from Fosun
• Positive Sentiment: New liver cancer trial update suggests potential longer-term oncology upside, adding to the narrative that successful Phase III execution could materially re-rate the stock over time. Pfizer’s New Liver Cancer Trial
• Neutral Sentiment: Analysts and industry write-ups (MarketBeat, Benzinga comparisons, and Motley Fool pieces) are weighing PFE versus peers (Merck, Eli Lilly) — useful context but varied conclusions; these pieces emphasize that Pfizer’s future returns hinge on pipeline execution and commercial recovery. Better Buy in 2026: Pfizer or Merck?
• Neutral Sentiment: One analyst summary notes PFE looks materially undervalued with a high forward yield, but warns upside is conditional on successful late‑stage trials and commercialization. This frames PFE as a yield/turnaround play rather than immediate growth. Pfizer Isn’t Dead Money
• Negative Sentiment: Pfizer issued a muted 2026 outlook and trimmed profit guidance, citing lower COVID sales and patent/exclusivity pressures; that guidance and the revenue/profit trims are the primary reasons shares fell today. Pfizer Down After Muted 2026 Outlook
• Negative Sentiment: Following the outlook, some brokers cut or softened ratings (average brokerage rating now around Hold), and the stock has taken analyst downgrades and short‑term selling pressure. Average Rating of Hold from Brokerages
• Negative Sentiment: High-profile commentary (Jim Cramer) highlighting management struggles adds to negative sentiment and short-term headline risk after the guidance release. Jim Cramer: CEO Struggling

Pfizer Price Performance

PFE stock opened at $25.19 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The company’s fifty day moving average price is $25.10 and its 200-day moving average price is $24.84. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The company has a market capitalization of $143.22 billion, a PE ratio of 14.65 and a beta of 0.46.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date is Friday, January 23rd. Pfizer’s payout ratio is currently 100.00%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.